Succinic acid mono-(4-[bis-(4-methoxy-phenyl)-phenyl-methoxymethyl]-1-{6-[17-(1,5-dimethyl-hexyl)-10,13-dimethyl2,3,4,7,8,9,10,11,12,13,14,15,16,17-tetradecahydro-1H cyclopenta[a]phenanthren-3-yloxycarbonylamino]-hexanoyl}-pyrrolidin-3-yl) ester 17-(1,5-dimethyl-hexyl)-10,13-dimethyl-2,3,4,7,8,9,10,11,12,13,14,15,16,17-tetradecahydro-1H-cyclopenta[a]phenanthren-3-yl ester

• 分子结构分类: 有机化合物 - 脂质和类脂质分子 - 类固醇和类固醇衍生物
• 英文名称: Succinic acid mono-(4-[bis-(4-methoxy-phenyl)-phenyl-methoxymethyl]-1-{6-[17-(1,5-dimethyl-hexyl)-10,13-dimethyl2,3,4,7,8,9,10,11,12,13,14,15,16,17-tetradecahydro-1H cyclopenta[a]phenanthren-3-yloxycarbonylamino]-hexanoyl}-pyrrolidin-3-yl) ester 17-(1,5-dimethyl-hexyl)-10,13-dimethyl-2,3,4,7,8,9,10,11,12,13,14,15,16,17-tetradecahydro-1H-cyclopenta[a]phenanthren-3-yl ester
• 英文别名: succinic acid mono-(4-[bis-(4-methoxy-phenyl)-phenyl-methoxymethyl]-1-{6-[17-(1,5-dimethyl-hexyl)-10,13-dimethyl 2,3,4,7,8,9,10,11,12,13,14,15,16,17-tetradecahydro-1H-cyclopenta[a]phenanthren-3-yloxycarbonylamino]-hexanoyl}-pyrrolidin-3-yl) ester；succinic acid mono-(4-[bis-(4-methoxy-phenyl)-phenyl-methoxymethyl]-1-{6-[17-(1,5-dimethyl-hexyl)-10,13-dimethyl-2,3,4,7,8,9,10,11,12,13,14,15,16,17-tetradecahydro-1H-cyclopenta[a]phenanthren-3-yloxycarbonylamino]-hexanoyl}-pyrrolidin-3-yl) ester；succinic acid mono-(4-[bis(4-methoxy-phenyl)-phenyl-methoxymethyl]-1-{6-[17-(1,5-dimethyl-hexyl)-10,13-dimethyl-2,3,4,7,8,9,10,11,12,13,14,15,16,17-tetradecahydro-1H-cyclopenta[a]phenanthren-3-yloxycarbonylamino]-hexanoyl}-pyrrolidin-3-yl)ester；4-[4-[[bis(4-methoxyphenyl)-phenylmethoxy]methyl]-1-[6-[[(3S,10R,13R,17R)-10,13-dimethyl-17-(6-methylheptan-2-yl)-2,3,4,7,8,9,11,12,14,15,16,17-dodecahydro-1H-cyclopenta[a]phenanthren-3-yl]oxycarbonylamino]hexanoyl]pyrrolidin-3-yl]oxy-4-oxobutanoic acid
• 化学式: C₆₄H₈₈N₂O₁₀
• 分子量: 1045.41
• InChiKey: NRLFEQKAYHGMPG-GVJWDZRTSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  13.3
• 重原子数：
  76
• 可旋转键数：
  26
• 环数：
  8.0
• sp3杂化的碳原子比例：
  0.62
• 拓扑面积：
  150
• 氢给体数：
  2
• 氢受体数：
  10

反应信息

• 作为产物：
  描述：

  丁二酸酐 、 (6-{3-[bis-(4-methoxy-phenyl)-phenyl-methoxymethyl]-4-hydroxy-pyrrolidin-1-yl}-6-oxo-hexyl)-carbamic acid 17-(1,5-dimethyl-hexyl)-10,13-dimethyl-2,3,4,7,8,9,10,11,12,13,14,15,16,17-tetradecahydro-1H-cyclopenta[a]phenanthren-3-yl ester 在 4-二甲氨基吡啶 、 三乙胺 作用下， 以 1,1-二氯乙烷 为溶剂， 反应 16.0h， 生成 Succinic acid mono-(4-[bis-(4-methoxy-phenyl)-phenyl-methoxymethyl]-1-{6-[17-(1,5-dimethyl-hexyl)-10,13-dimethyl2,3,4,7,8,9,10,11,12,13,14,15,16,17-tetradecahydro-1H cyclopenta[a]phenanthren-3-yloxycarbonylamino]-hexanoyl}-pyrrolidin-3-yl) ester 17-(1,5-dimethyl-hexyl)-10,13-dimethyl-2,3,4,7,8,9,10,11,12,13,14,15,16,17-tetradecahydro-1H-cyclopenta[a]phenanthren-3-yl ester
  参考文献：
  名称：

  Compositions and methods for inhibiting expression of the PCSK9 gene

  摘要：

  该发明涉及一种双链核糖核酸(dsRNA)，用于抑制前蛋白酶转化亚硫酸酯基肽酶9 (PCSK9) 基因的表达，包括具有核苷酸序列的反义链，其长度小于30个核苷酸，通常为19-25个核苷酸，并且与PCSK9基因的至少一部分基本互补。该发明还涉及包括dsRNA和药学上可接受的载体的药物组合物；以及使用该药物组合物治疗由PCSK9基因表达引起的疾病的方法。

  公开号：

  US07605251B2

文献信息

• Compositions and methods for inhibiting expression of huntingtin gene
  申请人：Sah Wen-Yee Dinah

  公开号：US20070099860A1

  公开（公告）日：2007-05-03

  The invention relates to a double-stranded ribonucleic acid (dsRNA) for inhibiting the expression of the Huntingtin gene (HD gene), comprising an antisense strand having a nucleotide sequence which is less than 25 nucleotides in length and which is substantially complementary to at least a part of the HD gene. The invention also relates to a pharmaceutical composition comprising the dsRNA together with a pharmaceutically acceptable carrier; methods for treating diseases caused by the expression of the HD gene, or a mutant form thereof, using the pharmaceutical composition; and methods for inhibiting the expression of the huntingtin gene in a cell.

  该发明涉及一种双链核糖核酸(dsRNA)，用于抑制Huntingtin基因(HD基因)的表达，包括具有核苷酸序列的反义链，其长度小于25个核苷酸，并且与HD基因的至少一部分基本互补。该发明还涉及包括dsRNA和药用载体的药物组合物；使用该药物组合物治疗由HD基因的表达或其突变形式引起的疾病的方法；以及在细胞中抑制huntingtin基因表达的方法。
• Compositions and Methods for Inhibiting Expression of XBP-1 Gene
  申请人：Fitzgerald Kevin

  公开号：US20130023580A1

  公开（公告）日：2013-01-24

  The invention relates to a double-stranded ribonucleic acid (dsRNA) targeting X-Box Protein 1 (XBP-1), and methods of using the dsRNA to inhibit expression of XBP-1.

  本发明涉及一种针对X-Box蛋白1（XBP-1）的双链核糖核酸（dsRNA），以及使用该dsRNA抑制XBP-1表达的方法。
• WO2007/56331
  申请人：——

  公开号：——

  公开（公告）日：——
• [EN] RNAI MODULATION OF AHA AND THERAPEUTIC USES THEREOF<br/>[FR] MODULATION D'AHA PAR L'ARN ET UTILISATEURS THÉRAPEUTIQUES DE CELLE-CI
  申请人：ALNYLAM PHARMACEUTICALS INC

  公开号：WO2007137156A8

  公开（公告）日：2009-12-17
• US8765932B2
  申请人：——

  公开号：US8765932B2

  公开（公告）日：2014-07-01